Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Abstract excerpt

Gain-of-function mutations in the genes encoding Janus kinases have been discovered in various haematologic diseases. Jaks are composed of a FERM domain, an SH2 domain, a pseudokinase domain and a kinase domain, and a complex interplay of the Jak domains is involved in regulation of catalytic activity and association to cytokine receptors. Most activating mutations are found in the pseudokinase domain. Here we...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Catalytic Domain
• Share to Drug Discovery
• Share to Enzyme Inhibitors